Time: 10.00 – 12.00 CEST, June 15th 2020
On June 15, Arocell AB provides a live broadcast business update with subsequent question time led by Redeye’s analyst Oscar Bergman.
CEO Michael Brobjer, together with parts of the management team, will among other things provide an update on the 510 (k) application for the US market and the company’s regulatory strategy. Furthermore, the plans for the upcoming launch in the US will be described.
Also, the presentation will provide an overview of the extensive clinical program, with a focus on being able to offer an early therapy response in the treatment of cancer, which means improved care for patients and lower costs for healthcare providers.
